Effect of linking bridge modifications on the antipsychotic profile of some phthalimide and isoindolinone derivatives

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 149-157

  Norman, Mark H ^a   Minick, Douglas J ^a   Rigdon, Greg C ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [4 (1,2 BENZISOTHIAZOL 3 YL) 1 PIPERAZINYL]BUTYL] 1 ISOINDOLINONE; 2 [4 [4 (1,2 BENZISOTHIAZOL 3 YL) 1 PIPERAZINYL]BUTYL]PHTHALIMIDE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; APOMORPHINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; ISOINDOLE DERIVATIVE; KETANSERIN; NEUROLEPTIC AGENT; PHTHALIMIDE DERIVATIVE; RACLOPRIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL BOND; CLIMBING; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EXTRAPYRAMIDAL SYMPTOM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BINDING, COMPETITIVE; BRAIN; CLOZAPINE; HALOPERIDOL; INDOLES; KETANSERIN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MOLECULAR CONFORMATION; PHTHALIMIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0030043026     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9502201     Document Type: Article

References (36)

1. Simpson, G. M.; Verga, E. Clozapine-A New Antipsychotic Agent. Curr. Ther. Res. 1974, 16, 679-686.
2. Vinick, F. J.; Kozlowski, M. R. Atypical Antipsychotic Agents. In Annual Reports in Medicinal Chemistry; Bailey, D. M., Ed.; Academic Press: New York, 1986; Vol. 21, pp 1-9.
3. Lowe, J. A., III; Seeger, T. F.; Vinick, F. J. Atypical Antipsychotics - Recent Findings and New Perspectives. Med. Res. Rev. 1988, 8, 475-497.
4. Jann, M. W. Clozapine. Pharmacotherapy 1991, 11, 179-195.
5. Bablenis, E.; Weber, S. S.; Wagner, R. L. Clozapine: A Novel Antipsychotic Agent. DICP 1989, 23, 109-115.
6. Meltzer, H. Y. Novel Approaches to the Pharmacotherapy of Schizophrenia. Drug Dev. Res. 1986, 9, 23-40.
7. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the Treatment-Resistant Schizophrenic. A Double-Blind Comparison With Chlorpromazine. Arch. Gen. Psychiatry 1988, 45, 789-796.
8. Griffith, R. W.; Saameli, K. Letter: Clozapine and Agranulocytosis. Lancet 1975, 2, 657.
9. Lieberman, J. A.; John, C. A.; Kane, J. M.; Rai, K.; Pisciotta, A. V.; Saltz, B. L.; Howard, A. Clozapine-induced Agranulocytosis: Non-cross-reactivity with Other Psychotropic Drugs. J. Clin. Psychiatry 1988, 49, 271-277.
10. Clozaril. Physicians' Desk Reference, 48th ed.; Medical Economics Data Production Co.: Montvale, NJ, 1994; pp 2042-2046.
11. 2 pK, Values. J. Pharmacol. Exp. Ther. 1989, 251, 238-246.
12. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 1988, 244, 685-693.
13. 2 Activity of a New Model of Arylpiperazines: 1-Aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and Structure-Activity Relationships. J. Med. Chem. 1994, 37, 99-104.
14. Hrib, N. J.; Jurcak, J. G.; Burgher, K. L.; Conway, P. G.; Hartman, H. B.; Kerman, L. L.; Roehr, J. E.; Woods, A. T. Benzisoxazole- and Benzisothiazole-3-carboxamides and Potential Atypical Antipsychotic Agents. J. Med. Chem. 1994, 37, 2308-2314.
15. Fontenla, J. A.; Osuna, J.; Rosa, E.; Castro, M. E.; G-Ferreiro, T.; Loza-Garcia, I.; Calleja, J. M.; Sanz, F.; Rodriguez, J.; Ravina, E.; Fueyo, J.; F-Masaguer, C.; Vidai, A.; de Ceballos, M. L. Synthesis and Atypical Antipsychotic Profile of some 2-(2-Piperidinoethyl)benzocycloalkanones as Analogues of Butyrophenone. J. Med. Chem. 1994, 37, 2564-2573.
16. Phillips, S. T.; de Paulis, T.; Baron, B. M.; Siegel, B. W.; Seeman, P.; Van Tol, H. H. M.; Guan, H.-C.; Smith, H. E. Binding of 5H-Dibenzo[b,e][1,4]diazeprae and Chiral 5H-Dibenzo[a,d]cycloheptene Analogues of Clozapine to Dopamine and Serotonin Receptors. J. Med. Chem. 1994, 37, 2686-2696.
17. 2 Affinity Ratios of Resolved 5,6,7,8,9,10-Hexahydro-7,10-iminocyclohept[b]indoles: An Enantioselective Approach Toward the Design of Potential Atypical Antipsychotics. J. Med Chem. 1993, 36, 3073-3076.
18. Hrib, N. J.; Jurcak, J. G.; Huger, F. P.; Errico, C. L.; Dunn, R. W. Synthesis and Biological Evaluation of a Series of Substituted N-Alkoxyimides and amides as Potential Atypical Antipsychotic Agents. J. Med. Chem. 1991, 34, 1068-1072.
19. 2 Receptor Antagonists: Potential Atypical Antipsychotic Agents. J. Med. Chem. 1994, 37, 2552-2563.
20. Treatment of trans-1,2-cyclopropanedimethanol with tosyl chloride-DMAP is reported to give the corresponding dichloride (Hwang, C. K.; Li, W. S.; Nicolaou, K. C. Reactions of Hydroxyl Groups with Tosylchloride-Dimethylaminopyridine System. Direct Synthesis of Chlorides from Hydroxycompounds. Tetrahedron Lett. 1984, 25, 2295-2296). In our hands, however, only the monochlorinated product was obtained.
21. Murata, K. Preparation, Polymerization, and Copolymerization of N-Vinyl Phthalimidine. Bull. Chem. Soc. Jpn. 1973, 46, 1752-1755.
22. Kato, K.; Yoshida, M. Diels-Alder Reaction of N-Vinylimides. Nipon Kagaku Zasshi, 1966, 87, 1098-1100.
23. Davies, W.; Perkins, W. H. The Chlorination and Bromination of the Toluic Acids and the Preparation of Phthalaldehydic Acids. J. Chem. Soc. 1922, 121, 2202-2215.
24. Lee, G. E.; Wragg, W. R. 5-(and 6-)Chloro-1-Oxoisoindoline Derivatives. U.K Patent 1,036,274, July 20, 1966.
25. 3H-Raclopride: A Potent Substituted Benzamide Drug with High Affinity for Dopamine D-2 Receptors in the Rat Brain. Biochem. Pharmacol. 1985, 34, 2251-2259.
26. 1c Binding Sites in Rat Frontal Cortex. J. Neurochem. 1986, 47, 529-540.
27. 2 Receptor Binding Sites. Binding Properties, Brain Distribution, and Functional Role. Mol. Pharmacol. 1982, 21, 301-314.
28. (a) Costall, B.; Naylor, R. J.; Nohria, V. Climbing Behaviour Induced by Apomorphine in Mice: A Potential Model for the Detection of Neuroleptic Activity. Eur. J. Pharmacol. 1978, 50, 39-50.
29. 50s (doses required for 50% of maximal response) were calculated on percent antagonism or percent inhibition by the method of Litchfield, J. T.; Wilcoxon, F. Simplified Method of Evaluating Dose-effect Experiments. J. Pharmacol. Exp. Ther. 1949, 96, 99-113 (Pharm/PCS Software, Philadelphia, PA).
30. 50s (concentrations that inhibited specific binding by 50%) were calculated by the method of Monod, J.; Changeux, J.-P.; Jocob, F. Allosteric Proteins and Cellular Control Systems J. Mol. Biol. 1963, 6, 306-329.
31. The X-ray crystal structure of isoindolinone 2 was determined by J. D. Ferrara of Molecular Structure Corp., 3200A Research Forest Dr., The Woodlands, TX.
32. MacroModel, version 4.5, Department of Chemistry, Columbia University, New York, NY 10027. See: Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MarcroModel - An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467. Note: The version of MM2* employed in these calculations did not contain sufficient parameters for the benzisothiazole heterocycle. Therefore, a bond length of 1.653 Å (obtained from the single X-ray analysis of isoindolinone 2) and an estimated force constant of 3.0 mdyn/Å were added to the parameter set for the N-S bond of the benzisothiazole ring.
33. MacroModel, version 4.5, Department of Chemistry, Columbia University, New York, NY 10027. See: Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MarcroModel - An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467. Note: The version of MM2* employed in these calculations did not contain sufficient parameters for the benzisothiazole heterocycle. Therefore, a bond length of 1.653 Å (obtained from the single X-ray analysis of isoindolinone 2) and an estimated force constant of 3.0 mdyn/Å were added to the parameter set for the N-S bond of the benzisothiazole ring.
34. Yevich, J. P.; New, J. S.; Smith, D. W.; Lobeck, W. G.; Catt, J. D.; Minielli, J. L.; Eison, M. S.; Taylor, D. P.; Riblet, L. A.; Temple, D. L., Jr. Synthesis and Biological Evaluation of 1-(1,2-Benzisothiazol-3-yl)- and (1,2-Benzisoxazol-3-yl)piperazine Derivatives as Potential Antipsychotic Agents. J. Med. Chem. 1986, 29, 359-369.
35. Ashton, W. T.; Meurer, L. C.; Cantone, C. L.; Field, A. K.; Hannah, J.; Karkas, J. D.; Liou, R.; Patel, G. F.; Perry, H. C.; Wagner, A. F.; Walton, E.; Tolman, R. L. Synthesis and Antiherpetic Activity of (±)-9-[[(Z)-2-(Hydroxymethyl)cyclopropyl]-methyl]quanine and Related Compounds. J. Med. Chem. 1988, 31, 2304-2315.
36. Chapman, J. M., Jr.; Cocolas, G. H.; Hall, I. H. Hypolipidemic Activity of Phthalimide derivatives. 3. A Comparison of Phthalimide and 1,2-Benzisothiazolin-3-one 1,1-dioxide Derivatives to Phthalimidine and 1,2-Benzisothiazoline 1,1-dioxide congeners. J. Med Chem. 1983, 26, 243-246.